A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Overactive Bladder
Interventions
DRUG

Solifenacin succinate

Trial Locations (10)

Unknown

Anyang

Bucheon-si

Busan

Cheonan

Daegu

Daejeon

Gwangju

Incheon

Seoul

Suwon

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma Korea, Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY

NCT00189800 - A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder | Biotech Hunter | Biotech Hunter